Immunogenicity of a new routine vaccination schedule for global poliomyelitis prevention: An open-label, randomised controlled trial

The Lancet

Volumn 386, Issue 10011, 2015, Pages 2413-2421

  Sutter, Roland W ^a   Bahl, Sunil ^a   Deshpande, Jagadish M ^b   Verma, Harish ^a   Ahmad, Mohammad ^a   Venugopal, P ^c   Rao, J Venkateswara ^d   Agarkhedkar, Sharad ^e   Lalwani, Sanjay K ^f   Kunwar, Abhishek ^a   Sethi, Raman ^a   Takane, Marina ^a   Mohanty, Lalitendu ^g   Chatterjee, Arani ^g,h   John, T Jacob ⁱ   Jafari, Hamid ^a   Aylward, R Bruce ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b Haffkine Institute for Training Research and Testing India   (India)

^c ANDHRA MEDICAL COLLEGE   (India)

^d GANDHI MEDICAL COLLEGE   (India)

^e HOSPITAL AND RESEARCH CENTRE   (India)

^f BHARATI VIDYAPEETH UNIVERSITY   (India)

^g Panacea Biotec Ltd   (India)

^h Biological E Ltd   (India)

ⁱ CHRISTIAN MEDICAL COLLEGE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

BIVALENT ORAL POLIOVIRUS VACCINE; INACTIVATED POLIOMYELITIS VACCINE; POLIOMYELITIS VACCINE; TRIVALENT ORAL POLIOVIRUS VACCINE; UNCLASSIFIED DRUG; IMMUNOLOGIC FACTOR; ORAL POLIOMYELITIS VACCINE; VIRUS ANTIBODY;

ANTIBODY TITER; APGAR SCORE; ARTICLE; ASPIRATION PNEUMONIA; BIRTH WEIGHT; BRONCHIOLITIS; BRONCHITIS; BRONCHOPNEUMONIA; CLINICAL PROTOCOL; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG FEVER; FAILURE TO THRIVE; FEMALE; FEMUR FRACTURE; GESTATIONAL AGE; HUMAN; HUMAN POLIOVIRUS 1; HUMAN POLIOVIRUS 2; HUMAN POLIOVIRUS 3; IMMUNE RESPONSE; IMMUNOGENICITY; INDIA; INFORMED CONSENT; MAJOR CLINICAL STUDY; MALE; MENINGITIS; MULTICENTER STUDY; NEONATAL HYPERBILIRUBINEMIA; NEWBORN; NEWBORN SEPSIS; OPEN STUDY; POLIOMYELITIS; POLIOMYELITIS VIRUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; SEROLOGY; SEROPREVALENCE; UMBILICAL CORD BLOOD; VACCINATION; VIRUS NEUTRALIZATION; ANTIBODY PRODUCTION; BLOOD; CLINICAL TRIAL; DISEASE ERADICATION; IMMUNIZATION; IMMUNOLOGY; PHYSIOLOGY; PROCEDURES;

ANTIBODIES, VIRAL; ANTIBODY FORMATION; DISEASE ERADICATION; FEMALE; HUMANS; IMMUNIZATION SCHEDULE; IMMUNOLOGIC FACTORS; INFANT, NEWBORN; MALE; POLIOMYELITIS; POLIOVIRUS; POLIOVIRUS VACCINE, INACTIVATED; POLIOVIRUS VACCINE, ORAL; SEROCONVERSION; VACCINATION;

EID: 84952636448     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(15)00237-8     Document Type: Article

References (30)

1. JE Hagan, SGF Wassilak, AS Craig et al. Progress towards polio eradication worldwide, 2014-2015 Wkly Epidemiol Rec 90 2015 253 259
2. CC Burns, OM Diop, RW Sutter, OM Kew Vaccine-derived polioviruses J Infect Dis 210 suppl 1 2014 S283 S293
3. Global Polio Eradication Initiative Polio Eradication and Endgame Strategic Plan 2013-2018 2013 World Health Organization Geneva
4. WHO Meeting of the Strategic Advisory Group of Experts on Immunization, November 2013 - conclusions and recommendations Wkly Epidemiol Rec 89 2014 1 19
5. WHO Polio vaccines: WHO position paper, January 2014 Wkly Epidemiol Rec 89 2014 73 92
6. E Vidor, SA Plotkin Poliovirus vaccine - inactivated SA Plotkin WA Orenstein PA Offit Vaccine 6th edn. 2013 Elsevier Saunders Philadelphia 573 597
7. RW Sutter, OM Kew, SL Cochi, RB Aylward Poliovirus vaccine - live SA Plotkin WA Orenstein PA Offit Vaccine 6th edition 2013 Elsevier Saunders Philadelphia 574 645
8. LN Alexander, JF Seward, TA Santibanez et al. Vaccine policy changes and epidemiology of poliomyelitis in the United States JAMA 292 2004 1696 1701
9. L Platt, C Estivariz, RW Sutter Vaccine-associated paralytic poliomyelitis: epidemiology and estimation of global burden J Infect Dis 210 suppl 1 2014 S380 S389
10. SAS/STAT user guide, version 6.4 (SAS Institute, Cary, NC, 4th edn, 1989), vol 1.
11. Expanded Programme on Immunization. Report of a WHO Informal Consultation on Polio Neutralizing Antibody Assays, Nashville, 5-6 December 1991. World Health Organization 1991 (document WHO/EPI/RD/91.3 Rev 1).
12. Department of Immunization Vaccines and Biologicals Polio laboratory manual 4th edn. 2004 World Health Organization Geneva (WHO/IVB/04.10).
13. R Development Core Team Vienna: R Foundation for Statistical Computing http://www.R-project.org 2005 (accessed March 22, 2015).
14. WJ Conover Practical nonparametric statistics 1971 John Wiley and Sons New York
15. C Clopper, ES Pearson The use of confidence or fiducial limits illustrated in the case of the binomial Biometrika 26 1934 404 413
16. B Effron, R Tibshirani An introduction to the bootstrap 1993 Chapman and Hall/CRC London
17. The Cuba IPV Collaborative Group Randomized, placebo-controlled trial of inactivated poliovirus vaccine in Cuba N Engl J Med 356 2007 1536 1544
18. TJ John, P Jayabal Oral polio vaccination of children in the tropics: I. The poor seroconversion rates and the absence of viral interference Am J Epidemiol 96 1972 263 269
19. PA Patriarca, PF Wright, TJ John Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: review Rev Infect Dis 13 1991 926 939
20. NC Grassly, C Fraser, J Wenger et al. New strategies for the elimination of polio from India Science 314 2006 1150 1153
21. H Jafari, JM Deshpande, RW Sutter et al. Efficacy of inactivated poliovirus vaccine in India Science 345 2014 922 925
22. S Chandir, KU Ahamed, AH Baqui et al. Effect of buffer on the immune response to trivalent oral poliovirus vaccine in Bangladesh: a community based randomized controlled trial J Infect Dis 210 suppl 1 2014 S390 S397
23. CF Estívariz, H Jafari, RW Sutter et al. Immunogenicity of supplemental doses of poliovirus vaccine for children aged 6-9 months in Moradabad, India: a community-based, randomised controlled trial Lancet Infect Dis 12 2012 128 135
24. RW Sutter, TJ John, H Jain et al. Immunogenicity of bivalent types 1 and 3 oral poliovirus vaccine: a randomised, double-blind, controlled trial Lancet 376 2010 1682 1688
25. MA Habib, S Soofi, A Sheraz et al. Zinc supplementation fails to increase the immunogenicity of oral poliovirus vaccine: a randomized controlled trial Vaccine 33 2015 819 825
26. F Mir, F Quadri, O Mach et al. Monovalent type 1 oral poliovirus vaccine administered at short interval: a randomized controlled trial in Pakistan Lancet Infect Dis 15 2015 889 897
27. S Resik, A Tejeda, RW Sutter et al. Priming after a fractional dose of inactivated poliovirus vaccine N Engl J Med 368 2013 416 424
28. S Iwarson, M Lindh, L Widerström Excellent booster response 4-8 years after a single primary dose of an inactivated hepatitis A vaccine J Travel Med 11 2004 120 121
29. S Resik, A Tejeda, O Mach et al. Immune responses after fractional doses of inactivated poliovirus vaccine using newly developed intradermal jet injectors: a randomized controlled trial in Cuba Vaccine 33 2015 307 313
30. Immunization System Management Group of the Global Polio Eradication Initiative Introduction of inactivated polio vaccine and switch from trivalent to bivalent oral poliovirus vaccine worldwide, 2013-2016 Wkly Epidemiol Rec 90 2015 337 343